GRIN1 and Cognitive impairment: Here, neither an effect of NMDAR1-abs serostatus on global cognitive performance, as estimated by linear regression, nor on global cognitive impairment, as estimated by logistic regression models was evident at either timepoint (6-months FU performance: βModel3 = −0.05; 95%CI = −0.03 to 0.12, p = 0.36 and 6-months FU impairment: ORModel3 = 1.7; 95%CI = 0.46 to 6.19, p = 0.39; 12-months FU performance: βModel3 = −0.04; 95%CI = −0.34 to 0.14, p = 0.40 and 12-months FU impairment: ORModel3 = 2.8; 95%CI = 0.74 to 11.06, p = 0.13).